$LGND: Ligand Reports Q3 Royalty Growth of 51%, Raises FY26 Adj. EPS Guidance

$LGND

$LGND – Ligand Reports Q3 Royalty Growth of 51%, Raises FY26 Adj. EPS Guidance

LIGAND PHARMACEUTICALS INC

2026-10-29 00:00:00 UTC · SEC_8K · All $LGND

?? Positive AI Sentiment (+3.5 / 10)

Q3 royalty revenue up 51% YoY to $70.3M; revenue guidance reaffirmed.
Full-Year 2026 Adjusted Diluted EPS guidance raised to $9.50–$9.75 (previously $9.00–$9.50).
GAAP Net Loss posted at $(28.5)M or $(1.43) per share due to fair value adjustments.